Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Total Current Liabilities (2016 - 2025)

BioCorRx (BICX) has disclosed Total Current Liabilities for 16 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 1.2% to $8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.3 million through Dec 2025, up 1.2% year-over-year, with the annual reading at $8.3 million for FY2025, 1.2% up from the prior year.
  • Total Current Liabilities hit $8.3 million in Q4 2025 for BioCorRx, down from $15.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $15.0 million in Q3 2025 to a low of $2.8 million in Q2 2021.
  • Historically, Total Current Liabilities has averaged $7.0 million across 5 years, with a median of $5.9 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: decreased 21.03% in 2021 and later skyrocketed 99.03% in 2025.
  • Year by year, Total Current Liabilities stood at $4.4 million in 2021, then increased by 22.28% to $5.4 million in 2022, then increased by 19.9% to $6.4 million in 2023, then rose by 27.62% to $8.2 million in 2024, then rose by 1.2% to $8.3 million in 2025.
  • Business Quant data shows Total Current Liabilities for BICX at $8.3 million in Q4 2025, $15.0 million in Q3 2025, and $14.6 million in Q2 2025.